I would not know, mate.
It could be that the MoA is similar to Dexrazoxane, or it could be something new entirely.
There is this new research that emerged recently investigating human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The researchers ran a bunch of tests and found iPSC-CMs from diffferent patients were either sensitive or resistant to doxorubicin-induced cardiotoxicity. DND microRNA-mediated repression inhibitor 1 (DND1) was shown to be a differentially expressed gene that determined sensitivity/resistance.
It could very well be that Zantrene targets this mechanism causing increased resistance to doxorubicin-induced cardiotoxicity.
Ann: Bisantrene shows potent anticancer activity in AML models, page-88
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $266.3M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.56 | $101.6K | 64.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7451 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 408 | 1 |
View Market Depth
| Last trade - 15.53pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.035 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.62 | $1.56 | 7255 | ||
| Last updated 15.57pm 05/06/2024 ? | |||||
| RAC (ASX) Chart |